A 21‑Valent Adult Pneumococcal Conjugate Vaccine (V116) Is Immunogenic and Well Tolerated in People Living with HIV: Results from STRIDE‑7
Highlights
– V116, a 21‑valent adult‑specific pneumococcal conjugate vaccine, elicited measurable opsonophagocytic activity (OPA) responses against all 21 vaccine serotypes in adults living with HIV.
– For the 13 serotypes shared with PCV15 and PPSV23, V116 responses at day 30 were generally similar to responses after PCV15 followed by PPSV23 at week 12; for the eight serotypes unique to V116, responses were higher than the comparator regimen.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.